Citadel Advisors’s NRX Pharmaceuticals NRXP Stock Holding History
Bought
Maintained
Sold
Other funds holding NRXP
BGI
Citadel Advisors's NRXP Position: Q3 2026 in Review
Citadel Advisors increased its NRX Pharmaceuticals (NRXP) stake by 9.8% in Q3 2026, buying an estimated $237K and bringing the position to 746,635 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #6519.
Citadel Advisors first reported a position in NRXP in Q3 2021 and has held it in 8 quarters since. The position peaked at $2.78M in Q2 2026. 50 funds tracked by Wall St. Rank hold NRXP as of Q3 2026.
- Citadel Advisors held 746,635 shares of NRX Pharmaceuticals worth $2.18M as of Q3 2026.
- Citadel Advisors bought 66,592 NRX Pharmaceuticals shares in Q3 2026, an estimated $237K.
- NRX Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #6519 holding.
- Citadel Advisors first reported a position in NRX Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
- Citadel Advisors's NRX Pharmaceuticals position peaked at $2.78M in Q2 2026.
- 50 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.